Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Top-down mirikizumab vs azathioprine in early moderate-to-severe ulcerative colitis
2025-522585-72-00Phase 4Authorised
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in autoimmune colitis comparing Top-down mirikizumab with Standard of care azathioprine (2 arms). Primary endpoint: Comprehensive disease control at Week 52. Planned start Sep 2025; status: authorised.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-522585-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522585-72-00.